Medical Advocates

Atazanavir (Reyataz)
 
Perinatal Data

New and Noteworthy
Journal Data
Conference Data





 

 

Atazanavir Main Page New/Newsworthy Home Page      

Last updated:  December 21, 2017
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
     

December 2017
 
 

Journal Citations
       

 
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Floridia M, Masuelli G, Ravizza M, et al  
J Antimicrob Chemother
. 2017 Dec 13
Abstract

Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates
Perry M, Taylor GP, Sabin CA, et al
HIV Med
. 2015 Jul 22.
Abstract

Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure
Himes SK, Huo Y, Siberry GK. et al 
J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):178-86.
Abstract

Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
Lê MP, Mandelbrot L, Descamps D,  et al 
Antivir Ther
. 2015 Jan 20.
Abstract

Atazanavir exposure is effective during pregnancy, regardless of tenofovir use.
Colbers A, Hawkins D, Hidalgo-Tenorio C,  et al
Antivir Ther
. 2014 Jul 3.
Abstract

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Else L, Jackson V, Brennan M, et al  

HIV Med. 2014 May 14.
Abstract

Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
Floridia M, Ravizza M, Masuelli G, et al
J Antimicrob Chemother. 2013 Dec 25
Abstract

Clinical and Pharmacogenetic Factors Affecting Neonatal Bilirubinemia Following Atazanavir Treatment of Mothers During Pregnancy.
Eley T, Huang SP, Conradie F,  et al
AIDS Res Hum Retroviruses
. 2013 Jul 19
Abstract

Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.
Eley T, Bertz R, Hardy H, Burger D.
Antivir Ther
. 2013;18(3):361-75.
Abstract

Pharmacokinetics of an Increased Atazanavir Dose with and without Tenofovir During the Third Trimester of Pregnancy.
Kreitchmann R, Best BM, Wang J, et al
J Acquir Immune Defic Syndr. 2013 Feb 7.
Abstract

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy.
Else L, Jackson V, Brennan M, et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18330.
Abstract

Monitoring the Risk of Birth Defects Associated with Atazanavir Exposure in Pregnancy.
Esker S, Albano J, Uy J
AIDS Patient Care STDS. 2012 Mar 9.
Abstract

Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children,
and Adolescents.
Kiser JJ, Rutstein RM, Samson P, et al
AIDS
. 2011 May 21.
Abstract

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Mandelbrot L, Mazy F, Floch-Tudal C, et al
Eur J Obstet Gynecol Reprod Biol
. 2011 Apr 12
Abstract

FULL-TEXT ARTICLE
Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy.
Mirochnick M, Best BM, Stek AM,  et al
J Acquir Immune Defic Syndr
. 2011 Jan 28
Paper


Conference Citations
       

 
Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacy and preterm delivery rates
M. Perry, K. Conway, S. Flanagan, et al
(7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention)
Abstract

Atazanavir in pregnancy: transplacental transfer and neonatal hyperbilirubinaemia
J. Lamber, V. Jackson, M. Lawless, et al
(7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention)
Abstract

POSTER
The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily
given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182
F. Conradie, C. Zorilla, D. Josipovic, et al  

(5th IAS Conference)

PDF Poster
      Abstract

Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
C. Ferreira, G. Morau, G. Peytavin,  et al
(XVII International AIDS Conference)
Abstract
 

Pharmacokinetics and clinical outcomes with Atazanavir 300 mg QD/ritonavir 100 mg (ATV/r) QD + ZDV/3TC
during the 3rd trimester of pregnancy in HIV+ women: interim results from BMS AI424182

T. Eley, E. Vandeloise, M. Child, et al    
(XVII International AIDS Conference)
Abstract
 
Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg
Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV+ Women

T Eley, E Vandeloise, M Child
(15th CROI)
Abstract

POSTER
Atazanavir Use in Pregnancy
Morris A 
(3rd IAS Conference)

PDF Poster


Atazanavir Main Page New/Newsworthy Home Page      

Atazanavir Perinatal Data